Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:GLCCI1 polymorphism rs37973 and asthma treatment response to inhaled corticosteroids
Authors:ID Rijavec, Matija, Klinika Golnik (Author)
ID Žavbi, Mateja, Klinika Golnik (Author)
ID Lopert, Anton (Author)
ID Fležar, Matjaž, Klinika Golnik (Author)
ID Korošec, Peter, Klinika Golnik (Author)
Files:URL URL - Source URL, visit http://www.jiaci.org/revistas/vol28issue3_3.pdf
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background. Asthma treatment response is highly variable and pharmacogenetic markers that predict treatment response would be one step closer to personalized treatment. GWAS studies have shown that polymorphisms GLCCI1 could be associated with asthma treatment response to inhaled corticosteroids (ICS). Materials and methods. We genotyped rs37973 of GLCCI1 in 208 adult asthma patients treated with ICS. Change in % predicted FEV1 was analysed after short-term (3 months) and after long-term (at least 3 years) treatment. Treatment success was defined as good when FEV1 decreased less than 30 ml/year. Results. After 3 months of treatment, change of % predicted FEV1 was higher in patients with GG genotype than in patients with AG+AA genotype, and this genotype dependent difference was only evident in non-smokers. Similar results were found after at least 3 years of treatment when all patients were analysed, in non-smokers and patients with atopy. Even though, no differences in treatment success (good vs. poor response) were observed when analysing the entire group of patients, genotype dependent treatment success was highly influenced by smoking and atopy. GG genotype was overrepresented in non-smokers and patients with atopy with good response. Conclusions. Rs37973 was associated with short- and long-term treatment response; however, there was a great influence of smoking and atopy on pharmacogenetic association. Furthermore, we found GG genotype to be associated with better treatment response, what is contrary to results found in GWAS.
Keywords:asthma -- diagnosis -- therapy, pharmacogenetics, genetic polymorphism, smoking, inhaled corticosteroids, atopy, GLCCI1, FEV1, rs37973
Publication status:Published
Publication version:Version of Record
Place of publishing:Španija
Publisher:Esmon Publicidad
Year of publishing:2018
Number of pages:str. 165-171
Numbering:Vol. 28, iss. 3
PID:20.500.12556/DiRROS-12914 New window
UDC:616.2
ISSN on article:1698-0808
DOI:10.18176/jiaci.0229 New window
COBISS.SI-ID:2048262769 New window
Copyright:© 2018 Esmon Publicidad, S.A.
Note:Soavtorji: Žavbi M, Lopert A, Fležar M, Korošec P; Nasl. z nasl. zaslona; Opis vira z dne 21. 3. 2018;
Publication date in DiRROS:16.12.2020
Views:2129
Downloads:536
Metadata:XML DC-XML DC-RDF
:
RIJAVEC, Matija, ŽAVBI, Mateja, LOPERT, Anton, FLEŽAR, Matjaž and KOROŠEC, Peter, 2018, GLCCI1 polymorphism rs37973 and asthma treatment response to inhaled corticosteroids. Journal of investigational allergology & clinical immunology [online]. 2018. Vol. 28, no. 3, p. 165–171. [Accessed 18 March 2025]. DOI 10.18176/jiaci.0229. Retrieved from: http://www.jiaci.org/revistas/vol28issue3_3.pdf
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Journal of investigational allergology & clinical immunology
Shortened title:J. investig. allergol. clin. immunol.
Publisher:Esmon Publicidad
ISSN:1698-0808
COBISS.SI-ID:524162329 New window

Secondary language

Language:Spanish
Keywords:astma -- diagnostika -- terapija, farmakogenetika, genetski polimorfizem, kajenje, inhalacijski kortikosteroidi, atopija


Back